Tidal Investments LLC Raises Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Tidal Investments LLC grew its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 68.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 36,742 shares of the medical device company's stock after buying an additional 14,872 shares during the period. Tidal Investments LLC's holdings in DexCom were worth $2,463,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. raised its position in DexCom by 128.8% in the 2nd quarter. Blue Trust Inc. now owns 881 shares of the medical device company's stock worth $100,000 after buying an additional 496 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of DexCom by 135.4% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 3,830 shares of the medical device company's stock valued at $434,000 after buying an additional 2,203 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of DexCom by 15.3% in the second quarter. Nisa Investment Advisors LLC now owns 68,460 shares of the medical device company's stock worth $7,762,000 after acquiring an additional 9,092 shares during the period. Apollon Wealth Management LLC lifted its holdings in DexCom by 0.7% in the second quarter. Apollon Wealth Management LLC now owns 22,143 shares of the medical device company's stock valued at $2,511,000 after acquiring an additional 163 shares during the period. Finally, Raymond James Financial Services Advisors Inc. grew its stake in shares of DexCom by 6.0% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 615,131 shares of the medical device company's stock valued at $69,744,000 after purchasing an additional 34,905 shares during the period. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research reports. Oppenheimer dropped their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Stifel Nicolaus boosted their price objective on DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, August 23rd. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Finally, Citigroup lifted their target price on shares of DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $98.00.

DexCom Stock Down 1.0 %

DXCM stock traded down $0.78 during trading on Monday, reaching $76.41. 4,013,199 shares of the company traded hands, compared to its average volume of 3,885,139. The company has a market capitalization of $29.85 billion, a price-to-earnings ratio of 46.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. The business has a 50 day simple moving average of $73.76 and a 200 day simple moving average of $84.04. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.